$ZTS

Bluetongue virus serotype 3 (BTV-3) has been confirmed in Scotland after spreading in England and Wales, with movement controls for susceptible animals due at least until Sept 9. Zoetis and AHDB discuss outbreak costs and vaccination economics, citing EU experience that vaccination coverage reduces incidence and mortality. Scottish guidance notes full protection can take up to six weeks.

Zoetis said the U.S. FDA granted Emergency Use Authorization for Simparica Trio to treat New World screwworm larvae infestations in dogs and puppies. Zoetis noted the product is not on-label for this use, though it is approved for other parasites. Zoetis also cited its Dectomax livestock portfolio. ZTS shares closed at $75.82, up 3.10%.

The FDA issued an emergency use authorization for Zoetis’ Simparica Trio (sarolaner, moxidectin, pyrantel) to treat New World screwworm (NWS) myiasis in dogs and puppies. The EUA covers treatment only, not prevention. FDA says evidence supports effectiveness and benefits outweigh risks, with prescription-only access via licensed veterinarians while the EUA remains active.

Reuters reports the FDA granted emergency use authorization for Zoetis’ Simparica TRIO to treat New World screwworm infestations in dogs and puppies. FDA said most U.S. dogs are low risk, but those in or traveling to identified areas, including parts of Texas and New Mexico, should be monitored. Simparica TRIO was approved in 2020 for other parasite indications.

Zoetis (ZTS) shares fell nearly 6% to $72.66 after Q2 results. The company reported weaker vet clinical visits and lower net average selling prices, which could pressure margins. Akamai (AKAM) traded near the lower end of its range after Q2 revenue rose 5.8% to $1.1B and cloud bookings totaled $2.8B. Seagate (STX) dropped to $812.76 after Q2 non-GAAP EPS of $5.71 and revenue up 48.8% to $3.63B.

Zoetis (ZTS) shares fell about 3.7% as investors focused on softer U.S. companion-animal demand and competitive pressure. The company said U.S. companion-animal sales declined in Q1, with weaker veterinary visit volumes, price-sensitive owners, and stronger competition in dermatology and parasiticides. Zoetis cut its 2026 outlook in May, lowering revenue growth and adjusted earnings expectations.

Zoetis said James “Jay” Saccaro was appointed EVP, CFO and COO effective Aug. 17, combining roles for the first time. Zillow added COO duties to CFO Jeremy Hofmann, effective Aug. 5, while COO Jun Choo stepped down for health. Owens Corning named Todd Fister president and COO, with Jonathan Collins as EVP and CFO. The article also cites broader CFO mandate trends.

Zoetis (ZTS) shares fell about 6% to $72.66 after Q2 results, with vet clinical visits down and lower net average selling prices potentially pressuring margins. Akamai (AKAM) traded near the lower end of its $110 to $130 range despite Q2 revenue up 5.8% to $1.1B and $2.8B cloud bookings. Seagate (STX) dropped to $812.76 after Q1 non-GAAP EPS of $5.71 and revenue up 48.8% to $3.63B.

Zoetis reported Q2 revenue of $2.47B, slightly below estimates, and adjusted EPS of $1.87, modestly above. It cut full-year revenue guidance to $9.22B and adjusted EPS guidance to $6.20 at the midpoint. Management cited weaker U.S. companion animal demand, tougher discounting competition, and margin pressure, while Diagnostics grew 12% and Livestock rose 11%.

Zoetis (NYSE:ZTS) reported Q2 declines in dermatology revenue, with global down 16% to $395M and U.S. down 18% to $251M, while the Simparica franchise was flat at $442M. Osteoarthritis pain revenue fell 3% to $147M. Companion diagnostics rose 12% to $118M and livestock rose 11% to $731M. Zoetis cut 2026 guidance to $9.12B-$9.32B revenue and $6.15-$6.25 adjusted EPS.